Loading companies…
Loading companies…
United Kingdom · Biotech · Enterprise software
Developing transformative, best-in-class neuropsychiatric therapies
| Announced | Round | Amount | Investors |
|---|---|---|---|
| Series B | $65M | Access Biotechnology — Role not disclosedBritish Business Bank — Role not disclosedCanaan Partners — Role not disclosedDeep Track Capital — Role not disclosedICG — Role not disclosedJanus Henderson Investors — Role not disclosedJefferson Life Sciences — Role not disclosedMarshall Wace — Role not disclosedSanofi Ventures — Role not disclosedSchroders Capital — Role not disclosedSR One — Role not disclosedSV Health Investors — Role not disclosed |